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doi:10.1016/j.ijid.2007.07.004Nocardia cyriacigeorgica: pulmonary infection
in a patient with Basedow—Graves disease and a
short review of reported cases
Nocardia species are aerobic and saprophytic actinomy-
cetes found all around the world. They invade the human
body from the environment via trauma and the respiratory
tract, and cause cutaneous, pulmonary, and systemic
nocardiosis in humans. There is no age, ethnic group,
or geographic variation in nocardiosis caused by the dif-
ferent Nocardia species, and the male to female ratio
for infection is 3 to 1.1 Nocardiosis is a rare infection
and almost half of all cases are immunocompromised
subjects.2—7
The taxonomy of Nocardia species is a complex issue and
more than 30 different species have been reported to date.8
The morphologic and phenotypic characterization of these
species is difficult and time-consuming, hence they have
been grouped mainly on the basis of their pattern of drug
resistance (types I—VI). Nocardia asteroides drug pattern
type VI has recently been identified as Nocardia cyriacigeor-
gica by use of the 16S rRNA gene amplification method.
Therefore, N. cyriacigeorgica is not really a new species,
but a new name given to a relatively common species.9,10 Thisbacterium was originally described by Yassin et al. with the
name N. cyriacigeorgici;11 its name was subsequently chan-
ged to N. cyriacigeorgica.
Few invasive forms of Nocardia species have been
reported in the literature.12—22 The case described herein
is the first in the literature involving pulmonary N. cyria-
cigeorgica infection in an immunocompromised patient
with Basedow—Graves disease. We also review the pre-
viously reported cases of N. cyriacigeorgica infections in
humans.
The case was a 37-year-old man who was started on
propylthiouracil treatment, 450 mg daily, for treatment of
Basedow—Graves disease. After approximately one year, an
orbital computerized tomography (CT) scan was performed,
and findings resembling a thyroid orbitopathy were found. He
was started on methylprednisolone treatment, 96 mg daily,
which was gradually tapered and ceased a month later; he
developed diabetes mellitus secondary to corticosteroid
treatment, which was controlled with appropriate diet and
gliclazide treatment.
In July 2003 following consultation at the ophthalmol-
ogy department, methylprednisolone treatment, 48 mg
daily, was started once more. In September 2003, while
under the corticosteroid treatment, he was admitted to
336 Correspondenceour hospital with complaints of lethargy, weight loss,
muscle weakness, dyspnea, cough, hemoptysis, blurred
and double vision, pain in the eye, generalized itching,
and papular lesions on his upper trunk. On physical exam-
ination, crackles were detected in the basal segments of
both lungs. Exophthalmia was detected in both eyes,
diffuse and bilateral enlargement of the thyroid gland
was noted, and muscle weakness was present in the lower
extremities. A posteroanterior chest X-ray showed multi-
ple sharp-edged homogenous masses as large as 6 cm in
diameter resembling metastases, with heterogeneous
increment in density in the lung parenchyma. In laboratory
evaluation his leukocyte count was 12.8  109/l with
90% neutrophils in the differential count, C-reactive pro-
tein level was 9.62 mg/dl, and blood glucose level was
319 mg/dl. On the second day, he had a fever of 39.0 8C. In
the chest CT, diffuse consolidations and calcifications were
detected in the lung parenchyma. His blood glucose was
regulated with insulin treatment.
Following consultation with the infectious diseases
department and after obtaining a sputum specimen, cefe-
pime 2 g iv every 12 hours, amikacin 1000 mg iv/day, tri-
methoprim—sulfamethoxazole (TMP—SMX 80/400 mg) four
tablets every 12 hours po, and amphotericin B deoxycholate
1 mg/kg/day iv were started. Direct microscopic examina-
tion of the sputum with modified Ziehl—Neelsen stain
showed many branching acid-fast bacilli (Figure 1). Sputum
cultures performed on four occasions grew Nocardia spp,
Candida spp, and Aspergillus fumigatus. Antibiotic suscept-
ibility testing with the E-test revealed resistance to TMP—
SMX (minimum inhibitory concentration (MIC) 0.064 mg/l)
and his serum aspergillus galactomannan test was found to
be negative; TMP—SMX and amphotericin B treatments
were ceased and vancomycin was added. Following the
determination of Nocardia spp as the causative agent this
was changed to imipenem 500 mg iv (MIC 0.125 mg/l) every
6 hours for 5 days, but unfortunately the patient died.
Although many attempts at treatment were undertaken,
the patient’s situation deteriorated. He died 30 days
after hospitalization due to acute circulatory failure and
disseminated infection that did not respond to medical
treatment.Figure 1 Modified Ziehl—Neelsen-stained direct preparation
from sputum.Our case was amale patient with an immunocompromising
condition (Basedow—Graves disease), long-term and high
dose corticosteroid usage, and resultant diabetes mellitus.
Mootsikapun et al. reported four cases with diabetes mellitus
and one case with Graves disease among their 70 cases of
nocardiosis,23 but there were no data on the species names of
the bacteria. Our patient’s symptoms, physical examination,
and radiological findings were in concordance with the symp-
toms and findings of pulmonary nocardiosis reported in the
literature.
A summary of reported nocardiosis cases with N. cyriaci-
georgica as the etiologic agent is shown in Table 1.
Kageyama et al. reported 31 cases affected by N. cyria-
cigeorgica in Japan,20 and in another report by the same
author, 27 cases — 19 in Japan and eight in Thailand.21
Poonwan et al. reported 13 strains of N. cyriacigeorgica in
Thailand.22 There were no data in these reports on the
clinical features of the cases, hence these series could not
be detailed in Table 1; we recommend the readers to see
original reports for further details.20—22
In terms of geographical distribution, N. cyriacigeorgica
seems to be predominant in Asian and European countries, as
reported cases have come from Japan, Thailand, Turkey,
Germany, and Spain.9,13—23 In the literature, all reported
cases have had the invasive disease, and there is only one
case report on this bacterium in a cat with cutaneous infec-
tion.24
In our patient, after finding branching acid-fast bacilli on
direct microscopy, sputum samples were cultured in blood
agar, chocolate agar, and Sabouraud’s dextrose agar, and
incubated for 2—4 weeks. The diagnosis of Nocardia was
obtained from our laboratory; the identification of N. cyria-
cigeorgica was performed by P. Boiron in the Mycology
Laboratory of Claude Bernard University using the 16S rRNA
gene amplification method.9,25
A total of 85 N. cyriacigeorgica cases have been
reported to date for which 27 of the infections have been
located in the lung, three in the brain, and one in the eye;
the infection sites of the remaining 54 cases were not
identified in the reports. According to Kageyama et al., the
combination of an aminoglycoside with imipenem acts
synergistically.20 In the literature, most of the improved
or resolved cases were treated with meropenem, amika-
cin, or ceftriaxone combination and oral TMP—SMX as
maintenance therapy (Table 1); it appears that the most
convenient combination is meropenem + amikacin. It
should be noted that this bacterium is resistant to beta-
lactams, ciprofloxacin, and some macrolides.26 Our patient
received a combination of cefepime, amikacin, and imi-
penem according to antibiogram test results. However,
since he was seriously immunodeficient and diabetic due
to long-term corticosteroid therapy, the condition resulted
in death.
In conclusion, N. cyriacigeorgica has the potential
to cause invasive infections in immunocompromised
patients. Nocardia infections should be borne in mind in
all cases with the probability of immune system derange-
ment and should be differentiated from other fungal and
mycobacterial infections and malignancies as quickly as
possible and treated promptly with aggressive combination
protocols.
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Table 1 Summary of reported cases of Nocardia cyriacigeorgica infection (adapted from Ansari et al.12)
Reference Age (years),
sex
Underlying disease and
concurrent infections
Systemic
corticosteroid use
Infection site Culture samples Treatment Infection outcome
Yassin et al. 11 NA Chronic bronchitis NA NA Bronchial secretion NA NA
Fux et al. 13 59, M RA Yes + methotrexate,
mycophenolate
Multifocal brain
abscesses
Abscess fluid Meropenem + amikacin +
ceftriaxone, TMP—SMX
Resolved
van Dam et al. 14 22, M Fungal pneumonia +
N. farcinica
No Lung BAL Meropenem + amikacin,
TMP—SMX
Improved
Barnaud et al. 15 33, F HIV infection No Brain abscess BAL Amoxicillin +
minocycline + TMP—SMX
Improved
Elsayed et al. 16 69, F Diabetes mellitus, chronic
lymphocytic leukemia
NA Lung, CNS, RAM Blood, adrenal
biopsy specimen
Meropenem, TMP—SMX Resolved
47, F Follicular non-Hodgkin
lymphoma, ASCT
NA Lung Blood Meropenem, TMP—SMX Resolved (died
from aspergillosis)
Alp et al. 17 72, M No No Multiple intracranial
abscesses
Sputum, abscess
material
Ceftriaxone + amikacin Improved
Arslan et al. 18 25, M Behcet’s disease Yes Lung, STA Abscess material Cefoperazone Died (from
pulmonary
embolism)
Mun˜oz et al. 19 74, M COPD Yes Lung NA Sulfadiazine Survived
58, M Heart transplant, diabetes Yes Lung NA TMP—SMX Survived
44, F COPD, RA Yes Lung NA TMP—SMX Survived
71, F COPD, lymphoma Yes Lung NA TMP—SMX Died
76, M COPD No Lung NA TMP—SMX Survived
79, M COPD No Lung NA Co-amoxiclav Survived
NA, not available; M, male; F, female; RA, rheumatoid arthritis; TMP—SMX, trimethoprim—sulfamethoxazole; BAL, bronchoalveolar lavage; CNS, central nervous system; RAM, right adrenal
mass; ASCT, allogeneic stem cell transplant; STA, soft tissue abscess; COPD, chronic obstructive pulmonary disease.
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